--- /Users/ray/code/ecfr-versioner/data/titles/preprocessed/xml/21/2017/01/2017-01-03_9b868f32.xml	2022-03-16 10:38:58.000000000 -0700
+++ tmp/title_version_21_2017-01-03_9b868f32_preprocessed.xml	2022-03-16 10:43:00.000000000 -0700
@@ -96044,11 +96044,18 @@
 <P>(b) <I>Record quality.</I> All records, including those not stored at the inspected establishment, must be legible, stored to prevent deterioration or loss, and readily available for review and copying by FDA employees.
 </P>
 <P>(c) <I>Record retention period.</I> You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.
+</P>
+
+</DIV8>
 
+</DIV6>
 
+</DIV5>
+
+<DIV5 N="216" TYPE="PART">
+<HEAD>PART 216 - HUMAN DRUG COMPOUNDING 
+</HEAD>
 
-&gt;PART 216 - HUMAN DRUG COMPOUNDING 
-</P>
 <CONTENTS>
 <SUBPART>
 <RESERVED>Subpart A - General Provisions [Reserved]
@@ -96068,15 +96075,12 @@
 <AUTH>
 <HED>Authority:</HED><PSPACE>21 U.S.C. 351, 352, 353a, 353b, 355, and 371.
 </PSPACE></AUTH>
-</DIV8>
 
 <SOURCE>
 <HED>Source:</HED><PSPACE>64 FR 10944, Mar. 8, 1999, unless otherwise noted.
 
 
 </PSPACE></SOURCE>
-</DIV6>
-
 
 <DIV6 N="A" TYPE="SUBPART">
 <HEAD>Subpart A - General Provisions [Reserved]</HEAD>
